WO2011031986A1 - Dosages du récepteur soluble à il-15 alpha - Google Patents

Dosages du récepteur soluble à il-15 alpha Download PDF

Info

Publication number
WO2011031986A1
WO2011031986A1 PCT/US2010/048451 US2010048451W WO2011031986A1 WO 2011031986 A1 WO2011031986 A1 WO 2011031986A1 US 2010048451 W US2010048451 W US 2010048451W WO 2011031986 A1 WO2011031986 A1 WO 2011031986A1
Authority
WO
WIPO (PCT)
Prior art keywords
sample
soluble
antibody
complex
amount
Prior art date
Application number
PCT/US2010/048451
Other languages
English (en)
Inventor
Jing Chen
Thomas Alexander Waldmann
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health
Publication of WO2011031986A1 publication Critical patent/WO2011031986A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

L'invention concerne un dosage sensible et spécifique permettant de quantifier de faibles taux d'IL-15Rα soluble dans n'importe quel échantillon de mammifère contenant ou présumé contenir sIL-15Rα, y compris des échantillons biologiques tels que du sérum, du plasma, un lysat tissulaire, un lysat de tumeur ou un surnageant de culture de cellules tumorales. Ces méthodes sont particulièrement appropriées pour un dosage immunoenzymatique (ELISA). L'invention concerne également des méthodes de diagnostic ou de surveillance de troubles associés à IL-15Rα-, notamment des leucémies, des lymphomes, des maladies auto-immunes, des maladies rétrovirales ou d'un choc septique induit par LPS. L'invention concerne également des méthodes de surveillance de l'efficacité d'un traitement thérapeutique qui augmente la quantité de sIL- 15Rα chez un patient, en particulier lorsque le traitement thérapeutique est LPS, un interféron, IL-15 ou IL-15Rα.
PCT/US2010/048451 2009-09-10 2010-09-10 Dosages du récepteur soluble à il-15 alpha WO2011031986A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24126509P 2009-09-10 2009-09-10
US61/241,265 2009-09-10
US24259509P 2009-09-15 2009-09-15
US61/242,595 2009-09-15

Publications (1)

Publication Number Publication Date
WO2011031986A1 true WO2011031986A1 (fr) 2011-03-17

Family

ID=42983831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048451 WO2011031986A1 (fr) 2009-09-10 2010-09-10 Dosages du récepteur soluble à il-15 alpha

Country Status (1)

Country Link
WO (1) WO2011031986A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311972A (zh) * 2016-06-15 2019-02-05 美国安进公司 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US20080227119A1 (en) 2006-10-04 2008-09-18 Genentech, Inc. ELISA for VEGF
US20080255039A1 (en) 2004-02-27 2008-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity
US20090018316A1 (en) 1994-05-06 2009-01-15 Anderson Dirk M Interleukin-15 receptors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US20090018316A1 (en) 1994-05-06 2009-01-15 Anderson Dirk M Interleukin-15 receptors
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US20080255039A1 (en) 2004-02-27 2008-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity
US20080227119A1 (en) 2006-10-04 2008-09-18 Genentech, Inc. ELISA for VEGF

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
BADOUAL C ET AL: "The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US LNKD- DOI:10.1158/0008-5472.CAN-07-6842, vol. 68, no. 10, 15 May 2008 (2008-05-15), pages 3907 - 3914, XP002488938, ISSN: 0008-5472 *
BADOUAL ET AL.: "The Soluble a Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer", CANCER RES., vol. 68, no. 10, 2008, pages 3907 - 3914
BERNARD J ET AL: "Identification of an interleukin-15alpha receptor-binding site on human interleukin-15", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M312458200, vol. 279, no. 23, 4 June 2004 (2004-06-04), pages 24313 - 24322, XP002286785, ISSN: 0021-9258 *
BESTE ET AL., PROC. NATL. ACAD. SCI., vol. 96, 1993, pages 1898 - 1903
BOUCHAUD G ET AL: "Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 138, no. 7, 1 June 2010 (2010-06-01), pages 2378 - 2387, XP027094499, ISSN: 0016-5085, [retrieved on 20100223] *
BUDAGIAN ET AL.: "Natural Soluble Interleukin-15Ra is Generated by Cleavage That Involves the Tumor Necrosis Factor-a-converting Enzyme (TACElADAM17)", J. BIOL. CHEM., vol. 279, no. 39, pages 40368 - 40375
BULANOVA E ET AL: "Soluble interleukin (IL)-15R[alpha] is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15", JOURNAL OF BIOLOGICAL CHEMISTRY 20070504 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, vol. 282, no. 18, 4 May 2007 (2007-05-04), pages 13167 - 13179, XP002607607, DOI: DOI:10.1074/JBC.M610036200 *
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
EMBO JOURNAL, vol. 14, 1995, pages 3654 - 3663
IMMUNITY, vol. 17, no. 5, 2002, pages 537 - 47
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MATSUMOTO M ET AL: "On-column refolding and characterization of soluble human interleukin-15 receptor alpha-chain produced in Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA LNKD- DOI:10.1016/S1046-5928(03)00143-8, vol. 31, no. 1, 1 September 2003 (2003-09-01), pages 64 - 71, XP004454317, ISSN: 1046-5928 *
MORTIER ERWAN ET AL: "IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US LNKD- DOI:10.1084/JEM.20071913, vol. 205, no. 5, 12 May 2008 (2008-05-12), pages 1213 - 1225, XP002571967, ISSN: 0022-1007 *
MORTIER ERWAN ET AL: "IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US LNKD- DOI:10.1084/JEM.20071913, vol. 205, no. 5, 12 May 2008 (2008-05-12), XP002607608, Retrieved from the Internet <URL:http://jem.rupress.org/content/suppl/2008/05/04/jem.20071913.DC1/1.html> [retrieved on 20101026] *
MORTIER ERWAN ET AL: "Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 3, 1 August 2004 (2004-08-01), pages 1681 - 1688, XP002445753, ISSN: 0022-1767 *
MORTIER ET AL.: "IL-15R? Chaperones IL-15 to Stable Dendritic Cell Membrane Complexes that Activate NK Cells via Trans Presentation", J. EXP. MED., vol. 205, no. 5, 2008, pages 1213 - 1225
MORTIER ET AL.: "Natural, Proteolytic Release of a Soluble Form of Human IL-1 5 Receptor a-Chain that Behaves as a Specific, High Affinity IL-15 Antagonist", J. IMMUNOLOGY, vol. 173, 2004, pages 1681 - 1688
MORTIER ET AL.: "soluble Interleukin-15 Receptor a (IL-15R?)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R?/?", J. BIOL. CHEM., vol. 281, no. 3, 2006, pages 1612 - 1619
RUCHATZ H ET AL: "SOLUBLE IL-15 RECEPTOR ALPHA-CHAIN ADMINISTRATION PREVENTS MURINE COLLAGEN-INDUCED ARTHRITIS: A ROLE FOR IL-15 IN DEVELOPMENT OF ANTIGEN-INDUCED IMMUNOPATHOLOGY", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 160, 1 January 1998 (1998-01-01), pages 5654 - 5660, XP002941876, ISSN: 0022-1767 *
TAGAYA Y ET AL., EMBO J., vol. 15, no. 18, 1996, pages 4928 - 493
WALDMANN: "The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design", NATURE REVIEW IMMUNOLOGY, vol. 6, 2006, pages 595 - 601

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311972A (zh) * 2016-06-15 2019-02-05 美国安进公司 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物

Similar Documents

Publication Publication Date Title
Hudson et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development
US10852302B2 (en) Method for evaluation of function of phagocyte
EP2564202B1 (fr) Détection d&#39;anticorps dirigés contre des anticorps thérapeutiques
US20090123415A1 (en) Diagnosis, treatment, and prevention of vascular disorders using il-1 autoantibodies
CN103154027A (zh) 可溶性人st-2抗体和分析法
JPH09506435A (ja) アレルギー診断法および抗アレルギー性治療剤のスクリーニング法
JP2020073870A (ja) 腎疾患のためのマーカー
US20180298072A1 (en) Diagnosis of a novel autoimmune disease
US7759075B2 (en) Molecules for the treatment of lung disease involving an immune reaction to connective tissue found in the lung
US20220056150A1 (en) Anti-factor ix padua antibodies
JP5437633B2 (ja) モノクローナル抗体およびその用途
Reggiani et al. Focal segmental glomerular sclerosis: do not overlook the role of immune response
Rajaei et al. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity
Buono et al. Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum
ES2425486T3 (es) Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
WO2011031986A1 (fr) Dosages du récepteur soluble à il-15 alpha
US20050282215A1 (en) Isolated cytokine receptor LICR-2
EP2923205B1 (fr) Analyse de la maladie de still survenant chez l&#39;adulte
Kim et al. Clinical significance of classification of Graves’ disease according to the characteristics of TSH receptor antibodies
CN114270191A (zh) 炎症性肠病诊断方法、诊断探针和诊断试剂盒
JP2019211230A (ja) ヒト由来サンプルにおける可溶型ｔｌｒ７の分析
JP3045172B2 (ja) Ｉｌ―６レセプターを利用したヒトｉｌ―６の化学的測定法及びそのためのキット
Fernandez Variable IL-2Rβ Expression and Organization in Signaling and Disease
US20120058110A1 (en) Method for Predicting the Responsiveness to an Anti-TNF Alpha Antibody Treatment
EP1385989A2 (fr) Inhibition de l&#39;il-1 en cas de myelome et troubles connexes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10755280

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10755280

Country of ref document: EP

Kind code of ref document: A1